Vericel Corp VCEL
We take great care to ensure that the data presented and summarized in this overview for Vericel Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VCEL
View all-
Black Rock Inc. New York, NY8.06MShares$334 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.49MShares$145 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD2.88MShares$120 Million3.98% of portfolio
-
State Street Corp Boston, MA2.44MShares$101 Million0.0% of portfolio
-
Invesco Ltd. Atlanta, GA2.27MShares$94.4 Million0.02% of portfolio
-
Conestoga Capital Advisors, LLC2.06MShares$85.6 Million1.39% of portfolio
-
Congress Asset Management CO1.48MShares$61.3 Million0.51% of portfolio
-
Gw&K Investment Management, LLC Boston, MA1.43MShares$59.4 Million0.59% of portfolio
-
Geneva Capital Management LLC1.37MShares$56.7 Million1.15% of portfolio
-
Wellington Management Group LLP Boston, MA1.36MShares$56.6 Million0.01% of portfolio
Latest Institutional Activity in VCEL
Top Purchases
Top Sells
About VCEL
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at VCEL
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 02
2025
|
Jonathan Mark Hopper Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,000
-13.12%
|
$400,000
$40.09 P/Share
|
Jun 02
2025
|
Jonathan Mark Hopper Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+11.6%
|
$180,000
$18.0 P/Share
|
May 15
2025
|
Dominick Colangelo President and CEO |
SELL
Open market or private sale
|
Direct |
14,063
-5.12%
|
$576,583
$41.53 P/Share
|
May 15
2025
|
Dominick Colangelo President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
14,063
+4.87%
|
$28,126
$2.65 P/Share
|
May 14
2025
|
Dominick Colangelo President and CEO |
SELL
Open market or private sale
|
Direct |
14,062
-5.12%
|
$590,604
$42.25 P/Share
|
May 14
2025
|
Dominick Colangelo President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
14,062
+4.87%
|
$28,124
$2.65 P/Share
|
May 07
2025
|
Kevin F Mclaughlin |
SELL
Open market or private sale
|
Direct |
7,000
-31.67%
|
$273,000
$39.98 P/Share
|
May 07
2025
|
Kevin F Mclaughlin |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+24.06%
|
$14,000
$2.76 P/Share
|
Apr 30
2025
|
Alan L Rubino |
BUY
Exercise of conversion of derivative security
|
Direct |
3,200
+6.5%
|
-
|
Apr 30
2025
|
Robert L Md Zerbe |
BUY
Exercise of conversion of derivative security
|
Direct |
3,200
+9.7%
|
-
|
Apr 30
2025
|
Paul K Wotton |
BUY
Exercise of conversion of derivative security
|
Direct |
3,200
+9.47%
|
-
|
Apr 30
2025
|
Kevin F Mclaughlin |
BUY
Exercise of conversion of derivative security
|
Direct |
3,200
+17.49%
|
-
|
Apr 30
2025
|
Lisa Wright |
BUY
Exercise of conversion of derivative security
|
Direct |
3,200
+20.19%
|
-
|
Apr 30
2025
|
Heidi Hagen |
BUY
Exercise of conversion of derivative security
|
Direct |
3,200
+9.13%
|
-
|
Apr 10
2025
|
Dominick Colangelo President and CEO |
SELL
Open market or private sale
|
Direct |
24,850
-8.71%
|
$1,018,850
$41.89 P/Share
|
Apr 10
2025
|
Dominick Colangelo President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
24,850
+8.01%
|
$49,700
$2.75 P/Share
|
Apr 09
2025
|
Dominick Colangelo President and CEO |
SELL
Open market or private sale
|
Direct |
24,850
-8.71%
|
$1,018,850
$41.11 P/Share
|
Apr 09
2025
|
Dominick Colangelo President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
24,850
+8.01%
|
$49,700
$2.75 P/Share
|
Mar 13
2025
|
Dominick Colangelo President and CEO |
SELL
Open market or private sale
|
Direct |
26,592
-9.28%
|
$1,196,640
$45.78 P/Share
|
Mar 13
2025
|
Dominick Colangelo President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
26,592
+8.49%
|
$26,592
$1.95 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 606K shares |
---|
Open market or private sale | 471K shares |
---|---|
Payment of exercise price or tax liability | 39.3K shares |